190 related articles for article (PubMed ID: 16872575)
21. Ritualistic Use of Ayahuasca versus Street Use of Similar Substances Seized by the Police: A Key Factor Involved in the Potential for Intoxications and Overdose?
Lanaro R; Calemi DB; Togni LR; Costa JL; Yonamine M; Cazenave Sde O; Linardi A
J Psychoactive Drugs; 2015; 47(2):132-9. PubMed ID: 25950593
[TBL] [Abstract][Full Text] [Related]
22. A narrative synthesis of research with 5-MeO-DMT.
Ermakova AO; Dunbar F; Rucker J; Johnson MW
J Psychopharmacol; 2022 Mar; 36(3):273-294. PubMed ID: 34666554
[TBL] [Abstract][Full Text] [Related]
23. Ayahuasca and the traveller: A scoping review of risks and possible benefits.
Houle SKD; Evans D; Carter CA; Schlagenhauf P
Travel Med Infect Dis; 2021; 44():102206. PubMed ID: 34785376
[TBL] [Abstract][Full Text] [Related]
24. Administration of N,N-dimethyltryptamine (DMT) in psychedelic therapeutics and research and the study of endogenous DMT.
Barker SA
Psychopharmacology (Berl); 2022 Jun; 239(6):1749-1763. PubMed ID: 35064294
[TBL] [Abstract][Full Text] [Related]
25. Psychedelic 5-methoxy-N,N-dimethyltryptamine: metabolism, pharmacokinetics, drug interactions, and pharmacological actions.
Shen HW; Jiang XL; Winter JC; Yu AM
Curr Drug Metab; 2010 Oct; 11(8):659-66. PubMed ID: 20942780
[TBL] [Abstract][Full Text] [Related]
26. A placebo-controlled study of the effects of ayahuasca, set and setting on mental health of participants in ayahuasca group retreats.
Uthaug MV; Mason NL; Toennes SW; Reckweg JT; de Sousa Fernandes Perna EB; Kuypers KPC; van Oorsouw K; Riba J; Ramaekers JG
Psychopharmacology (Berl); 2021 Jul; 238(7):1899-1910. PubMed ID: 33694031
[TBL] [Abstract][Full Text] [Related]
27. Human pharmacology of ayahuasca: subjective and cardiovascular effects, monoamine metabolite excretion, and pharmacokinetics.
Riba J; Valle M; Urbano G; Yritia M; Morte A; Barbanoj MJ
J Pharmacol Exp Ther; 2003 Jul; 306(1):73-83. PubMed ID: 12660312
[TBL] [Abstract][Full Text] [Related]
28. N,N-dimethyltryptamine and Amazonian ayahuasca plant medicine.
James E; Keppler J; L Robertshaw T; Sessa B
Hum Psychopharmacol; 2022 May; 37(3):e2835. PubMed ID: 35175662
[TBL] [Abstract][Full Text] [Related]
29. Pharmacology of ayahuasca administered in two repeated doses.
Dos Santos RG; Grasa E; Valle M; Ballester MR; Bouso JC; Nomdedéu JF; Homs R; Barbanoj MJ; Riba J
Psychopharmacology (Berl); 2012 Feb; 219(4):1039-53. PubMed ID: 21842159
[TBL] [Abstract][Full Text] [Related]
30. The clinical pharmacology and potential therapeutic applications of 5-methoxy-N,N-dimethyltryptamine (5-MeO-DMT).
Reckweg JT; Uthaug MV; Szabo A; Davis AK; Lancelotta R; Mason NL; Ramaekers JG
J Neurochem; 2022 Jul; 162(1):128-146. PubMed ID: 35149998
[TBL] [Abstract][Full Text] [Related]
31. Effects of Ayahuasca and its Alkaloids on Drug Dependence: A Systematic Literature Review of Quantitative Studies in Animals and Humans.
Nunes AA; Dos Santos RG; Osório FL; Sanches RF; Crippa JA; Hallak JE
J Psychoactive Drugs; 2016; 48(3):195-205. PubMed ID: 27230395
[TBL] [Abstract][Full Text] [Related]
32. Nonlinear pharmacokinetics of 5-methoxy-N,N-dimethyltryptamine in mice.
Shen HW; Jiang XL; Yu AM
Drug Metab Dispos; 2011 Jul; 39(7):1227-34. PubMed ID: 21464174
[TBL] [Abstract][Full Text] [Related]
33. The pharmacological interaction of compounds in ayahuasca: a systematic review.
Ruffell S; Netzband N; Bird C; Young AH; Juruena MF
Braz J Psychiatry; 2020; 42(6):646-656. PubMed ID: 32638916
[TBL] [Abstract][Full Text] [Related]
34. A case report SPECT study and theoretical rationale for the sequential administration of ibogaine and 5-MeO-DMT in the treatment of alcohol use disorder.
Barsuglia JP; Polanco M; Palmer R; Malcolm BJ; Kelmendi B; Calvey T
Prog Brain Res; 2018; 242():121-158. PubMed ID: 30471678
[TBL] [Abstract][Full Text] [Related]
35. Pharmepéna-Psychonautics: Human intranasal, sublingual and oral pharmacology of 5-methoxy-N,N-dimethyl-tryptamine.
Ott J
J Psychoactive Drugs; 2001; 33(4):403-7. PubMed ID: 11824699
[TBL] [Abstract][Full Text] [Related]
36. Stimulus control by 5-methoxy-N,N-dimethyltryptamine in wild-type and CYP2D6-humanized mice.
Winter JC; Amorosi DJ; Rice KC; Cheng K; Yu AM
Pharmacol Biochem Behav; 2011 Sep; 99(3):311-5. PubMed ID: 21624387
[TBL] [Abstract][Full Text] [Related]
37. A critical review of reports of endogenous psychedelic N, N-dimethyltryptamines in humans: 1955-2010.
Barker SA; McIlhenny EH; Strassman R
Drug Test Anal; 2012; 4(7-8):617-35. PubMed ID: 22371425
[TBL] [Abstract][Full Text] [Related]
38. Inhibition of alpha oscillations through serotonin-2A receptor activation underlies the visual effects of ayahuasca in humans.
Valle M; Maqueda AE; Rabella M; Rodríguez-Pujadas A; Antonijoan RM; Romero S; Alonso JF; Mañanas MÀ; Barker S; Friedlander P; Feilding A; Riba J
Eur Neuropsychopharmacol; 2016 Jul; 26(7):1161-75. PubMed ID: 27039035
[TBL] [Abstract][Full Text] [Related]
39. Effects of ayahuasca on the endocannabinoid system of healthy volunteers and in volunteers with social anxiety disorder: Results from two pilot, proof-of-concept, randomized, placebo-controlled trials.
Dos Santos RG; Rocha JM; Rossi GN; Osório FL; Ona G; Bouso JC; Silveira GO; Yonamine M; Marchioni C; Crevelin EJ; Queiroz ME; Crippa JA; Hallak JEC
Hum Psychopharmacol; 2022 Jul; 37(4):e2834. PubMed ID: 35107855
[TBL] [Abstract][Full Text] [Related]
40. Determination of N,N-dimethyltryptamine in beverages consumed in religious practices by headspace solid-phase microextraction followed by gas chromatography ion trap mass spectrometry.
Gaujac A; Dempster N; Navickiene S; Brandt SD; de Andrade JB
Talanta; 2013 Mar; 106():394-8. PubMed ID: 23598143
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
